CORT News and Press, Corcept Therapeutics Incorporated From 02/07/26

NEW YORK, NY - February 7, 2026 ( NEWMEDIAWIRE ) -  Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Corcept Therapeutics, Inc. (“Corcept” or the “Company”) (NASDAQ: CORT). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT TH...

NEW YORK, NY - February 6, 2026 ( NEWMEDIAWIRE ) -  Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Corcept Therapeutics, Inc. (“Corcept” or the “Company”) (NASDAQ: CORT). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT TH...

2026-02-06 09:10:00 ET The DeepSeek ( DEEPSEEK ) sell-off late last January, followed by the tariff tantrum in early April, caused US stocks to plummet. From peak to trough, the S&P 500 ( SPX ) fell 19% on a closing basis, just shy of bear market territory, while the Tech-he...

NEW YORK, NY - February 5, 2026 ( NEWMEDIAWIRE ) -  Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Corcept Therapeutics, Inc. (“Corcept” or the “Company”) (NASDAQ: CORT). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT TH...

2026-02-05 08:00:00 ET Showcase Intro In January, we welcomed 27 new analysts who published their first-ever article on Seeking Alpha. In this article, our editors highlight some of the best ideas from these new analysts and introduce them.... Read the full article on Seeking ...

2026-02-03 08:52:33 ET Xeris Pharmaceuticals' ( XERS ) shares have surged nearly 100% year-over-year (YoY) as a result of both strong and accelerating commercial revenue growth, improving operational discipline, and positive results from its pipeline. Today, Xeris represents mor...

NEW YORK, NY - February 3, 2026 ( NEWMEDIAWIRE ) -  Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Corcept Therapeutics, Inc. (“Corcept” or the “Company”) (NASDAQ: CORT). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT TH...

NEW YORK, NY - February 2, 2026 ( NEWMEDIAWIRE ) -  Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Corcept Therapeutics, Inc. (“Corcept” or the “Company”) (NASDAQ: CORT). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT TH...

Hagens Berman, a national shareholder rights law firm, is investigating whether Corcept Therapeutics Inc. (NASDAQ: CORT) misled investors about relacorilant’s efficacy and commercial prospects. Corcept is under renewed scrutiny after Reuters reported on Jan. 30, 2026, that the FDA ...

2026-01-30 09:19:35 ET More on Corcept Therapeutics Why Corcept Therapeutics' Relacorilant Fell Short And What It Means For The Company Corcept: Korlym Defies Generics As Relacorilant Hits An FDA CRL (Rating Upgrade) Corcept Therapeutics: Despite FDA Blind Side, Rela...